

STANDARD COMMERCIAL DRUG FORMULARY PRIOR AUTHORIZATION GUIDELINES

CLASCOTERONE

| Generic | Brand | HICL | GCN | Medi-Span | Exception/Other |
|--------------|---------|-------|-----|--------------|-----------------|
| CLASCOTERONE | WINLEVI | 46803 | | GPI-10 | |
| | | | | (9005001100) | |

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

- 1. Does the patient have a diagnosis of acne vulgaris and meet **ALL** of the following criteria?
 - The patient is 12 years of age or older
 - Therapy is prescribed by or given in consultation with a dermatologist
 - The patient had a trial of or contraindication to **BOTH** of the following:
 - ONE oral acne agent (e.g. oral antibiotics or oral isotretinoin)
 - TWO topical acne agents (e.g. topical retinoids, topical antibiotics, benzoyl peroxide)

If yes, approve for 3 months by HICL or GPI-10 with a quantity limit of #60 grams (1 tube) per 30 days.

APPROVAL TEXT: Renewal requires the patient had improvement of acne lesions.

If no, do not approve.

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **CLASCOTERONE** (Winlevi) requires the following rule(s) be met for approval:

- A. You have acne vulgaris (skin condition in which hair follicles become plugged with oil and dead skin cells)
- B. You are 12 years of age or older
- C. Therapy is prescribed by or given in consultation with a dermatologist (skin doctor)
- D. You have previously tried BOTH of the following unless there is a medical reason why you cannot (contraindication):
 - 1. ONE oral acne agent (such as oral antibiotics or oral isotretinoin)
 - 2. TWO topical acne agents (such as topical retinoids, topical antibiotics, benzoyl peroxide)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE

Copyright © 2021 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

11/20/2020 Page 1 of 2



STANDARD COMMERCIAL DRUG FORMULARY PRIOR AUTHORIZATION GUIDELINES

CLASCOTERONE

GUIDELINES FOR USE (CONTINUED)

RENEWAL CRITERIA

- 1. Does the patient have a diagnosis of acne vulgaris **AND** meet the following criterion?
 - The patient had improvement of acne lesions

If yes, approve for 12 months by HICL or GPI-10 with a quantity limit of #60 grams (1 tube) per 30 days.

If no, do not approve.

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **CLASCOTERONE** (Winlevi) requires the following rule(s) be met for approval:

- A. You have acne vulgaris (skin condition in which hair follicles become plugged with oil and dead skin cells)
- B. You had improvement of acne lesions

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Winlevi.

REFERENCES

Winlevi [Prescribing Information]. Milan, Italy: Cosmo S.p.A.; August 2020.

| Library | Commercial | NSA |
|---------|------------|-----|
| Yes | Yes | No |

Part D Effective: N/A Created: 12/20

Commercial Effective: 01/01/21 Client Approval: 12/20 P&T Approval: 10/20

Copyright © 2021 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

11/20/2020 Page 2 of 2